Download Full Text (4.4 MB)
- Zeroing In on a Moving Target
- New Life for an Old Drug
- House Call: Managing Your Medications
- DiaLog: Adjuvant Therapy for Aggressive Kidney Cancer, by Christopher G. Wood, MD, Associate Professor of Urology and Cancer Biology
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
The University of Texas MD Anderson Cancer Center
Krishnan, Sunil; Beddar, Sam; Briere, Tina; Weber, Donna Rose; Barlogie, B. (Bart); Dimopoulos, Meletios; Fidler, Isaiah J., 1936-; Lutgendorf, Susan; Corwin, Julie; Tran, Kim; Sood, Anil, M.D; Four-Dimensional Computed Tomography; Hepatitis B; Hepatitis C; Liver Transplantation; Carcinoma, Hepatocellular; Thalidomide; Myelodysplastic Syndromes; Multiple Myeloma; Lenalidomide; Lenalidomide; Cell Line; Antibodies, Monoclonal, Bortezomib; VAD protocol; Antineoplastic Combined Chemotherapy Protocols; Myeloablative Agonists; Stem Cell Transplantation; Dexamethasone; Prostatic Neoplasms -- secondary; Receptor, Platelet-Derived Growth Factor alpha; Clinical Trials as Topic; Imatinib Mesylate; Docetaxel; Paclitaxel; Ovarian Neoplasms; Stress, Psychological; Adrenergic beta-Antagonists; Medication Therapy Management; Kidney Neoplasms; Chemotherapy, Adjuvant; Carcinoma, Renal Cell; Receptors, Adrenergic
History of Science, Technology, and Medicine | Oncology
Chalaire, Dawn; Siy, Angelique; and Wood, Christopher G. MD, "OncoLog Volume 51, Number 09, September 2006" (2006). OncoLog MD Anderson's Report to Physicians (All issues). 186.
Conditions Governing Access